Jaffetilchin Investment Partners’s 10x Genomics TXG Stock Holding History

Jaffetilchin Investment Partners’s Portfolio TXG Stock Details TXG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-1,045	Closed	-$23.6K	–	1236
2024 Q3	$23.6K	Buy	+1,045	New	+$21.6K	﹤0.01%	729
2022 Q1	–	Sell	-9,433	Closed	-$1.41M	–	386
2021 Q4	$1.41M	Sell	9,433 -1,757	-16%	-$269K	0.13%	104
2021 Q3	$1.63M	Sell	11,190 -1,252	-10%	-$215K	0.17%	91
2021 Q2	$2.08M	Buy	12,442 +5,039	+68%	+$912K	0.14%	113
2021 Q1	$1.34M	Buy	7,403 +760	+11%	+$131K	0.16%	110
2020 Q4	$941K	Buy	6,643 +4,991	+302%	+$724K	0.13%	112
2020 Q3	$206K	Buy	+1,652	New	+$173K	0.04%	211

Other funds holding TXG

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Jaffetilchin Investment Partners's TXG Position: Q4 2024 in Review

Jaffetilchin Investment Partners sold out of 10x Genomics (TXG) in Q4 2024, closing a stake of 1,045 shares — an estimated $23.6K sold.

Jaffetilchin Investment Partners first reported a position in TXG in Q3 2020 and held it in 7 quarters. The position peaked at $2.08M in Q2 2021. 273 funds tracked by Wall St. Rank hold TXG as of Q4 2024.

Jaffetilchin Investment Partners reported no remaining 10x Genomics position as of Q4 2024 after selling out during the quarter.
Jaffetilchin Investment Partners sold 1,045 10x Genomics shares in Q4 2024, an estimated $23.6K.
Jaffetilchin Investment Partners first reported a position in 10x Genomics in Q3 2020 and held it in 7 quarters.
Jaffetilchin Investment Partners's 10x Genomics position peaked at $2.08M in Q2 2021.
273 funds tracked by Wall St. Rank held 10x Genomics as of Q4 2024.

Based on Jaffetilchin Investment Partners's 13F filing for Q4 2024, filed 13 Feb 2025.